Evidence map›Paper›PMID 40456600›Full record

Observational studyThorax2025

Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening.

Andrew W Creamer, Carolyn Horst, Ruth Prendecki, Priyam Verghese, Amyn Bhamani, Helen Hall, Sophie Tisi, Jennifer L Dickson, Chuen R Khaw, John McCabe and 12 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thorax, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Andrew W CreamerLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID 0000-0002-9314-1210
Carolyn HorstLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID 0000-0003-2427-6610
Ruth PrendeckiLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Priyam VergheseLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Amyn BhamaniLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID 0000-0002-8575-6119
Helen HallLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Sophie TisiLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Jennifer L DicksonLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID 0000-0002-9333-8320
Chuen R KhawLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
John McCabeLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Tanita LimaniUniversity College London Hospitals NHS Foundation Trust, London, UK.
Kylie GyertsonUniversity College London Hospitals NHS Foundation Trust, London, UK.
Anne-Marie HackerCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Jonathan TeagueCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Laura FarrellyCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Shrinkhala DawadiCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Neal NavaniUniversity College London Hospitals NHS Foundation Trust, London, UK.ORCID 0000-0002-6412-7516
Allan HackshawCancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
Anand DevarajRoyal Brompton Hospital, London, UK.
Arjun NairUniversity College London Hospitals NHS Foundation Trust, London, UK.ORCID 0000-0001-9270-3771
SUMMIT Consortium
Sam M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London, UK s.janes@ucl.ac.uk.ORCID 0000-0002-6634-5939

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundProspective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in solid nodules at baseline low-dose CT (LDCT) in a lung cancer screening (LCS) programme.

methodsThis was an observational study using data from the SUMMIT Study, a prospective longitudinal study investigating LDCT for LCS. Participants were 55-77 years old and met either the United States Preventative Services Task Force (2013) criteria or had a PLCO

results11 355 participants were included. Crude risk of malignancy in solid nodules at baseline LDCT was 3.8% (228/5929). Risk of malignancy in solid nodules <6 mm long-axis diameter or <100 mm

conclusionsSolid nodules <100 mm

Indexed as

Early Detection of CancerLung NeoplasmsMultiple Pulmonary NodulesSolitary Pulmonary NoduleTomography, X-Ray ComputedAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedPredictive Value of TestsProspective StudiesRisk AssessmentImaging/CT MRI etcLung Cancer

Identifiers

PMID40456600
PMCPMC12421124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.